EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Multiplexed, Target-Based Phenotypic Screening Platform Using CRISPR Interference in Mycobacterium abscessus

Donavan Marcus Neo, Ishay Ben-Zion iD, Josephine Bagnall, Matthew Y Solomon, Austin N Bond iD, Emily Gath, Shuting Zhang, Noam Shoresh, James Gomez, Deborah T Hung iD

ACS Infectious Diseases · 2025

DOI: 10.1021/acsinfecdis.5c00623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, 2025. Verfasst von Donavan Marcus Neo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Integrated Solutions for Infectious Diseases, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Anti-Bacterial Agents, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rise of difficult-to-treat Mycobacterium abscessus infections presents a growing clinical challenge due to the immense arsenal of intrinsic, inducible and acquired antibiotic resistance mechanisms that render many existing antibiotics ineffective against this pathogen. Moreover, the limited success in discovery of novel compounds that inhibit novel pathways underscores the need for innovative drug discovery strategies. Here, we report a strategic advancement in PROSPECT (PRimary screening Of Strains to Prioritize Expanded Chemistry and Targets), which is an antimicrobial discovery strategy that measures chemical-genetic interactions between small molecules and a pool of bacterial mutants, each depleted of a different essential protein target, to identify whole-cell active compounds with high sensitivity. Applying this modified strategy to M. abscessus, in contrast to previously described versions of PROSPECT which utilized protein degradation or promoter replacement strategies for generating engineered hypomorphic strains, here we leveraged CRISPR interference (CRISPRi) to more efficiently generate mutants each depleted of a different essential gene involved in cell wall synthesis or located at the bacterial surface. We applied this platform to perform a pooled PROSPECT pilot screen of a library of 782 compounds using CRISPRi guides as mutant barcodes. We identified a range of active hits, including compounds targeting InhA, a well-known mycobacterial target but under-explored in the M. abscessus space. The unexpected susceptibility to isoniazid, traditionally considered to be ineffective in M. abscessus, suggested a complex interplay of several intrinsic resistance mechanisms. While further complementary efforts will be needed to change the landscape of therapeutic options for M. abscessus, we propose that PROSPECT with CRISPRi engineering provides an increasingly accessible, high-throughput target-based phenotypic screening platform and thus represents an important step toward accelerating early stage drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusAnti-Bacterial AgentsClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsMicrobial Sensitivity TestsMycobacterium Infections, NontuberculousDrug DiscoveryBacterial ProteinsPhenotypeHumans

Stichwörter der Autor:innen

CRISPR interferenceMycobacterium abscessusantibiotic discoverychemical–genetic interactionscompound screeninghigh-throughput multiplexed screeningisoniazid intrinsic resistance

Substanzen

Anti-Bacterial AgentsBacterial Proteins

Autor:innen und Institutionen

  • Center for Integrated Solutions for Infectious Diseases, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
  • Department of Molecular Biology and Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
  • Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, United States.

ORCID-Profile: Ishay Ben-Zion, Austin N Bond, Deborah T Hung

Zitieren

APA

Neo, D. M., Ben-Zion, I., Bagnall, J., Solomon, M. Y., Bond, A. N., Gath, E., Zhang, S., Shoresh, N., Gomez, J., & Hung, D. T. (2025). A Multiplexed, Target-Based Phenotypic Screening Platform Using CRISPR Interference in Mycobacterium abscessus. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.5c00623

Vancouver

Neo DM, Ben-Zion I, Bagnall J, Solomon MY, Bond AN, Gath E, et al. A Multiplexed, Target-Based Phenotypic Screening Platform Using CRISPR Interference in Mycobacterium abscessus. ACS Infectious Diseases. 2025. doi:10.1021/acsinfecdis.5c00623

BibTeX
@article{Neo2025,
  author = {Neo, Donavan Marcus and Ben-Zion, Ishay and Bagnall, Josephine and Solomon, Matthew Y and Bond, Austin N and Gath, Emily and Zhang, Shuting and Shoresh, Noam and Gomez, James and Hung, Deborah T},
  title = {A Multiplexed, Target-Based Phenotypic Screening Platform Using CRISPR Interference in Mycobacterium abscessus},
  journal = {ACS Infectious Diseases},
  year = {2025},
  doi = {10.1021/acsinfecdis.5c00623}
}
Kostenlos starten →